Recent progress in aptamer-based microfluidics for the detection of circulating tumor cells and extracellular vesicles
- Author:
Duanping SUN
1
,
2
;
Ying MA
;
Maoqiang WU
;
Zuanguang CHEN
;
Luyong ZHANG
;
Jing LU
Author Information
1. Guangdong Provincial Key Laboratory of Pharmaceutical Bioactive Substances,Center for Drug Research and Development,Guangdong Pharmaceutical University,Guangzhou,510006,China
2. Key Specialty of Clinical Pharmacy,The First Affiliated Hospital of Guangdong Pharmaceutical University,Guangzhou,510699,China
- Keywords:
Aptamer;
Microfluidic;
Circulating tumor cells;
Extracellular vesicles;
Bioanalysis
- From:
Journal of Pharmaceutical Analysis
2023;13(4):340-354
- CountryChina
- Language:Chinese
-
Abstract:
Liquid biopsy is a technology that exhibits potential to detect cancer early,monitor therapies,and predict cancer prognosis due to its unique characteristics,including noninvasive sampling and real-time analysis.Circulating tumor cells(CTCs)and extracellular vesicles(EVs)are two important components of circu-lating targets,carrying substantial disease-related molecular information and playing a key role in liquid biopsy.Aptamers are single-stranded oligonucleotides with superior affinity and specificity,and they can bind to targets by folding into unique tertiary structures.Aptamer-based microfluidic platforms offer new ways to enhance the purity and capture efficiency of CTCs and EVs by combining the advantages of microfluidic chips as isolation platforms and aptamers as recognition tools.In this review,we first briefly introduce some new strategies for aptamer discovery based on traditional and aptamer-based micro-fluidic approaches.Then,we subsequently summarize the progress of aptamer-based microfluidics for CTC and EV detection.Finally,we offer an outlook on the future directional challenges of aptamer-based microfluidics for circulating targets in clinical applications.
